It’s been a busy week for Optimum, with some amazing original content from our clients, with this week’s podcast highlighting their expertise in cutting-edge lung cancer research. In our weekly hot topic article, they give predictions for the 2025 outlook following November’s London Life Sciences Week. We also have five clients nominated for the prestigious […]
In October, at our 15th Annual Healthcare Investor Conference, we announced our chosen charity for the year, Ariana Smiles. Ariana Smiles is a Special Named Fund at the Children’s Cancer and Leukaemia Group, raising funds for research into precision oncology medicine for children with leukaemia. Stephanie Seales Gabbitas and her husband Chris set up Ariana […]
A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application to the U.S. FDA, seeking approval of ensifentrine as a maintenance therapy. In the latest episode of Optimum Perspectives podcast, Eva Haas caught up with Chris Martin, Senior Vice President of Commercial, who […]
YOUNG biotech companies need “patient investors” with “deep pockets” to weather today’s financial storms, the head of Novo Holdings Seed Investments has told the Optimum Perspectives podcast. In an in-depth interview, Søren Møller said fledgling firms should accept it might be some time before investor confidence returns to the sector – and they need to […]
Calliditas is one of European biopharma’s big success stories, bringing a rare disease drug to market and commercializing it using its own sales force. Richard Staines from Optimum Strategic Communications spoke with CEO Renée Aguiar-Lucander who outlined the challenges the company has faced on its journey. Lengthy experience as a life science investor has helped […]
